https://www.studyops.com/11627-2/ 2017-04-25T18:03:54+00:00 https://www.studyops.com/merck-drug-works-vytorin-study-proves-successful/ 2014-11-20T21:46:24+00:00 https://www.studyops.com/wp-content/uploads/2014/11/Screen-Shot-2014-11-20-at-10.32.33-AM.png https://www.studyops.com/fda-approves-new-hard-to-abuse-hydrocodone-pill/ 2014-11-21T15:11:05+00:00 https://www.studyops.com/quorum-reviews-new-offering-for-phase-i-ebola-studies/ 2014-11-21T15:17:38+00:00 https://www.studyops.com/c-suite-unrest-in-big-pharma/ 2014-11-25T18:22:48+00:00 https://www.studyops.com/studyops-and-optimus-medical-awarded-2-hiv-trials/ 2014-11-25T18:54:18+00:00 https://www.studyops.com/studyops-awarded-fibromyalgia-clinical-trial-screening-will-begin-in-december/ 2014-11-26T16:21:09+00:00 https://www.studyops.com/wp-content/uploads/2014/11/Fibro.png https://www.studyops.com/hiv-losing-its-edge-evolving-into-milder-form-study-finds/ 2014-12-02T18:50:22+00:00 https://www.studyops.com/otsuka-expands-in-neurologic-diseases-with-deal-to-buy-avanir-for-3-5-billion/ 2014-12-02T19:43:45+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Avanir.png https://www.studyops.com/studyops-is-aggressively-recruiting-rheumatologist-principal-investigators-for-ra-trials/ 2014-12-03T17:56:36+00:00 https://www.studyops.com/wp-content/uploads/2014/12/RA.jpg https://www.studyops.com/the-debate-over-the-cost-to-develop-a-new-drug/ 2014-12-03T19:56:30+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Drugs.jpg https://www.studyops.com/fda-acceptance-of-smaller-clinical-trials-offers-upside-to-biotech-stocks/ 2014-12-05T15:36:09+00:00 https://www.studyops.com/wp-content/uploads/2014/12/btk.png https://www.studyops.com/the-biotech-index-is-more-than-a-triple-bagger-ramp-since-2010/ 2014-12-05T15:45:24+00:00 https://www.studyops.com/wp-content/uploads/2014/12/btk1.png https://www.studyops.com/merck-acquiring-cubist-focusing-on-hospital-care/ 2014-12-08T17:32:59+00:00 https://www.studyops.com/wp-content/uploads/2014/12/cubist.png https://www.studyops.com/pharmas-top-10-ma-deals-of-2014s-first-half/ 2014-12-09T17:13:42+00:00 https://www.studyops.com/wp-content/uploads/2014/12/merger-aqusition.jpg https://www.studyops.com/valeant-puts-dealmaking-on-hold-to-focus-on-the-bottom-line/ 2014-12-10T15:48:41+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Axkman.jpg https://www.studyops.com/the-cost-to-develop-a-new-drug-balloons-up-to-2-6b/ 2014-12-11T19:50:31+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Cost.jpg https://www.studyops.com/5-12-year-low-on-crude-oil/ 2014-12-15T21:33:49+00:00 https://www.studyops.com/wp-content/uploads/2014/12/WTI.png https://www.studyops.com/russian-stock-exchange-ouch/ 2014-12-16T17:36:14+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Russia.png https://www.studyops.com/crude-oil-closes-at-48-01-down-50-from-august/ 2015-01-07T01:09:27+00:00 https://www.studyops.com/wp-content/uploads/2015/01/Oil06JAN15.png https://www.studyops.com/an-upside-break-of-554-on-the-pharma-index-means-off-to-the-races-again/ 2015-01-08T21:29:03+00:00 https://www.studyops.com/wp-content/uploads/2015/01/drg554.png https://www.studyops.com/stocks-and-commodities-head-south-holiday-sales-failed-pharma-holds-tight/ 2015-01-14T16:17:53+00:00 https://www.studyops.com/wp-content/uploads/2015/01/INDU_Weekly_14Jan.png https://www.studyops.com/swiss-markets-slide-hard-roche-novartis-actelion-and-lonza-shares-plummet/ 2015-01-15T23:20:05+00:00 https://www.studyops.com/wp-content/uploads/2015/01/Swiss_Market.png https://www.studyops.com/jjs-boss-says-pharma-unit-fastest-growing-in-the-drug-business/ 2015-01-21T00:19:35+00:00 https://www.studyops.com/wp-content/uploads/2015/01/JNJ1.png https://www.studyops.com/merck-pulls-victrelis-in-the-u-s-gilead-and-abbvie-still-rule-hep-c/ 2015-01-21T18:35:37+00:00 https://www.studyops.com/wp-content/uploads/2015/01/MRK.png https://www.studyops.com/valeants-move-to-walk-away-from-allergan-bodes-well-for-the-shares/ 2015-01-22T18:04:05+00:00 https://www.studyops.com/wp-content/uploads/2015/01/VRX.png https://www.studyops.com/gilead-gild-pharma-101-excellent-management-happy-investors/ 2015-01-23T17:25:46+00:00 https://www.studyops.com/wp-content/uploads/2015/01/GILD.png https://www.studyops.com/abilify-patent-expiration-sends-bms-top-line-2015-forecast-south/ 2015-01-27T18:59:29+00:00 https://www.studyops.com/wp-content/uploads/2015/01/BMY.png https://www.studyops.com/amgen-blows-out-4th-q-with-profits-up-27/ 2015-01-28T00:29:28+00:00 https://www.studyops.com/wp-content/uploads/2015/01/AMGN.png https://www.studyops.com/gilead-gets-the-united-health-nod-for-hep-c-treatment-harvoni/ 2015-01-29T18:07:52+00:00 https://www.studyops.com/wp-content/uploads/2015/01/GILD2.png https://www.studyops.com/more-adverse-event-red-tape-from-the-fda-good-or-bad/ 2015-02-03T18:49:01+00:00 https://www.studyops.com/wp-content/uploads/2015/02/SO-Logo-Lab-Jkt.jpg https://www.studyops.com/gilead-announces-blow-out-numbers-but-the-shares-fall/ 2015-02-04T18:34:49+00:00 https://www.studyops.com/wp-content/uploads/2015/02/GILD04feb2015.png https://www.studyops.com/gsk-tees-up-the-viiv-spinoff-again/ 2015-02-04T20:24:24+00:00 https://www.studyops.com/wp-content/uploads/2015/02/GSK.png https://www.studyops.com/hospira-pops-39-on-pfizers-90-bid/ 2015-02-05T16:55:12+00:00 https://www.studyops.com/wp-content/uploads/2015/02/HSP.png https://www.studyops.com/alkermes-ramps-5-on-phase-i-top-line-data/ 2015-02-11T01:51:19+00:00 https://www.studyops.com/wp-content/uploads/2015/02/ALKS.png https://www.studyops.com/rd-for-cns-is-not-dead/ 2015-02-11T23:27:42+00:00 https://www.studyops.com/wp-content/uploads/2015/02/RHHBY.png https://www.studyops.com/gild-pops-on-insider-1-million-buy-in/ 2015-02-12T01:28:23+00:00 https://www.studyops.com/wp-content/uploads/2015/02/GILD11FEB.png https://www.studyops.com/abbvie-shares-on-hold-until-hcv-drug-and-biosimilar-humira-give-visibility/ 2015-02-17T20:42:15+00:00 https://www.studyops.com/wp-content/uploads/2015/02/ABBV.png https://www.studyops.com/shires-vyvanse-for-binge-eating-disorder-yes-no-maybe/ 2015-02-26T15:33:59+00:00 https://www.studyops.com/wp-content/uploads/2015/02/Shire.png https://www.studyops.com/kite-spends-21-million-for-t-cell-factory-and-adds-450-million-to-mkt-cap/ 2015-03-20T14:38:51+00:00 https://www.studyops.com/wp-content/uploads/2015/03/Kite.png https://www.studyops.com/novartis-pharmaceuticals-announces-a-joint-investment-company-with-qualcomm/ 2017-04-25T18:03:49+00:00 https://www.studyops.com/wp-content/uploads/2015/01/QCOM.png https://www.studyops.com/dont-use-generic-lyrica-for-pain-pfizer-warns-u-k-providers-or-else/ 2017-04-25T18:03:49+00:00 https://www.studyops.com/wp-content/uploads/2015/01/PFE.png https://www.studyops.com/reading-between-the-lines-is-the-pfizer-boss-thinking-conversion/ 2017-04-25T18:03:49+00:00 https://www.studyops.com/wp-content/uploads/2015/02/PFE.png https://www.studyops.com/labcorp-takes-down-covance-for-6-1-billion-deal-approved/ 2017-04-25T18:03:49+00:00 https://www.studyops.com/wp-content/uploads/2015/02/CVD.png https://www.studyops.com/wp-content/uploads/2015/02/q.png https://www.studyops.com/pfizer-turns-the-sex-talk-toward-50-ish-women-with-menopause-awareness-push/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Natural-Menopause-Treatments4.jpg https://www.studyops.com/isis-pharma-bad-name-hot-pipeline-major-ramp-to-new-highs/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2014/12/isis_pharmaceuticals_stock.ai_r620x349.jpg https://www.studyops.com/auspex-pharma-soars-on-huntingtons-disease-drug-trial/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2014/12/ASPX.png https://www.studyops.com/the-top-10-patent-losses-of-2015/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Patent.jpg https://www.studyops.com/opko-health-opk-just-signed-a-worldwide-partnership-deal-with-pfizer-receives-295-million/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2014/12/OPK.png https://www.studyops.com/gsk-ready-to-ax-hundreds-in-u-s-as-advair-sales-plummet/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2014/12/GSK.png https://www.studyops.com/salix-ceo-takes-a-hike-in-latest-fallout-from-inventory-snafu/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2015/01/Salix.png https://www.studyops.com/cancer-fighting-cytomx-lands-20-million-pfizer-investment-makes-key-hires/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2015/01/CytomX.jpg https://www.studyops.com/increases-in-womens-clinical-trial-participation-bring-uneven-gains/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2015/01/CT-Woms.jpg https://www.studyops.com/hedge-fund-exec-aims-new-legal-weapon-at-big-pharmas-evergreened-patents/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2015/01/kyle-bass-hedge-fund-has-taken-a-stake-in-general-motors-scaled.jpg https://www.studyops.com/gilead-buying-vertex-among-bold-biotech-stock-predictions-for-2015/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2015/01/VRTX.png https://www.studyops.com/shire-to-buy-biopharma-company-nps-pharma-for-5-2-billion-up-80-from-october/ 2017-04-25T18:03:50+00:00 https://www.studyops.com/wp-content/uploads/2015/01/NPSP.png https://www.studyops.com/more-pharma-shake-up-takedas-u-s-chief-bows-out/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/takeda-pharmaceutical-co-scaled.gif https://www.studyops.com/did-merck-pay-3b-too-much-for-cubist/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/cubist-2.jpg https://www.studyops.com/crude-oil-getting-decimated-not-another-govt-rescue-please/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Oil.png https://www.studyops.com/biotech-entrepreneur-tony-coles-takes-aim-at-parkinsons-and-alzheimers/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/logo.png https://www.studyops.com/groundbreaking-research-is-uncovering-better-ways-to-keep-aids-at-bay/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/n-HIV-large570.jpg https://www.studyops.com/puma-biotech-delays-breast-cancer-drug-filing-to-fda/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/puma.png https://www.studyops.com/mylan-receives-tentative-fda-approval/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/myland.png https://www.studyops.com/teva-sets-2015-sales-forecast-up-to-1b-lower-than-analysts-expected/ 2017-04-25T18:03:51+00:00 https://www.studyops.com/wp-content/uploads/2014/12/Teva.png https://www.studyops.com/health-experts-say-no-to-randomized-trials-testing-ebola-drugs/ 2017-04-25T18:03:53+00:00 https://www.studyops.com/should-the-fda-force-drug-makers-to-discuss-their-clinical-trials/ 2017-04-25T18:03:53+00:00 https://www.studyops.com/wp-content/uploads/2014/12/FDA-Approved.jpg https://www.studyops.com/payers-hep-c-delay-tactics-work-coverage-hurdles-may-be-dampening-harvoni-script-growth/ 2017-04-25T18:03:54+00:00 https://www.studyops.com/world-drug-bill-will-reach-1-3-trillion-by-2018/ 2017-04-25T18:03:54+00:00 https://www.studyops.com/wp-content/uploads/2014/11/Screen-Shot-2014-11-20-at-2.16.31-PM.png https://www.studyops.com/10-million-child-deaths-attributed-to-a-lack-of-toilets/ 2017-04-25T18:03:54+00:00 https://www.studyops.com/wp-content/uploads/2014/11/Screen-Shot-2014-11-20-at-2.33.02-PM.png